DRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alpha Tau Medical Ltd (DRTS) shows potential for long-term growth due to its innovative radiopharma platform and recent clinical advancements. However, given the lack of immediate revenue realization, neutral trading sentiment, and no strong proprietary trading signals, it is not an optimal buy for a beginner investor seeking long-term gains at this moment. Holding off for further developments or a clearer entry point is recommended.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), with MACD above 0 and positively contracting. RSI is neutral at 62.621. Key resistance levels are at 8.314 and 8.62, while support levels are at 7.32 and 7.014. The stock is trading near its resistance levels, suggesting limited immediate upside.
Broader-than-expected Japan approval for Alpha DaRT in head and neck cancer, leading to partnership opportunities.
Successful initiation of the ACAPELLA trial in Europe for pancreatic cancer, indicating clinical expansion.
Analysts have raised price targets, with Citi and H.C. Wainwright maintaining Buy ratings.
Piper Sandler downgraded the stock to Neutral, citing valuation concerns and a lack of near-term revenue realization.
The company's path to full commercialization is still 2-3 years away.
No significant trading trends from hedge funds or insiders.
In Q4 2025, the company reported no revenue growth (0% YoY), a net loss of $12.14M (improved by 28.07% YoY), and an EPS of -0.14 (unchanged YoY). Gross margin remains at 0%. The financials indicate a pre-revenue stage company with improving losses but no immediate profitability.
Analysts are mixed. Citi and H.C. Wainwright are optimistic, with price targets of $9 and $12, respectively, citing the company's innovative platform and Japan approval. Piper Sandler downgraded the stock to Neutral, citing valuation concerns and the lack of near-term revenue realization.
